News
-
-
PRESS RELEASE
NuRAN Closes Non-Brokered Private Placement of Convertible Debenture with a Single Placeholder
NuRAN Wireless Inc. announces the closing of a US$1.6 million unsecured convertible debenture private placement. Debenture features 15% interest rate and conversion into units at CDN$0.225 per Unit -
PRESS RELEASE
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55 -
PRESS RELEASE
Beyond Oil Announces Publication of Medical Opinion by Professor Sarel Halahmi, Head of Urology Department at Bnei Zion Medical Center-Medical Opinion Concluding that Beyond Oil is Improving Health Safety by Reducing Urological Risks, Bladder Cancer and I
Medical opinion highlights health risks of reusing frying oil, citing risks like bladder cancer and infertility. Beyond Oil's filter powder offers a solution. Expert urges global adoption for public health benefits -
-
PRESS RELEASE
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials -
PRESS RELEASE
Ivanhoe Electric and Ma'aden Joint Venture Commences Drilling Activities in Saudi Arabia
Ivanhoe Electric Inc. and Ma'aden Joint Venture to commence drilling in Saudi Arabia following Typhoon™ anomaly detection in Al Amar Belt. Exploration activities expanding into Bir Umq, Wadi Bidah and platform license applications -
-
PRESS RELEASE
Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05
Tanvex BioPharma USA, Inc. receives FDA approval for NYPOZI™ biosimilar and FDA BLA acceptance for TX-05, showcasing expertise in biologics development and manufacturing -
